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ABSTRACT 
The chemistry of gold nanoparticles (AuNPs) facilitates surface modifications and thus these 
bioengineered NPs have been investigated as a means of delivering a variety of therapeutic 
cargos to treat cancer. In this study we have developed AuNPs conjugated with targeting 
ligands to enhance cell-specific uptake in prostate cancer cells. First, negatively charged 
AuNPs-citrate were synthesised in water by reducing hydrochloroauric acid (HAuCl4.3H2O) 
with sodium citrate, subsequently an ethylene glycol based cross-linker (NHS-PEG-S-S-
PEG-NHS, the capping agent) was used to attach transferrin (Tf, the targeting ligand) onto 
the AuNPs-citrate producing transferrin-conjugated AuNPs (AuNPs-PEG-Tf). Secondly, 
positively charged AuNPs-PEI were obtained in water by reducing HAuCl4.3H2O using 
ascorbic acid in the presence of polyethylenimine (PEI, the capping agent), and folic acid 
(FA, the targeting ligand) was attached onto the AuNPs-PEI to produce folic acid-conjugated 
AuNPs (AuNPs-PEI-FA). Both bioconjugated AuNPs demonstrated low cytotoxicity in 
prostate cancer cells. The attachment of the targeting ligand Tf to AuNPs successfully 
achieved receptor-mediated cellular uptake in PC-3 cells, a prostate cancer cell line highly 
expressing Tf receptors. The AuNPs-PEI-FA effectively complexed small interfering RNA 
(siRNA) through electrostatic interaction. At the cellular level the AuNPs-PEI-FA 
specifically delivered siRNA into LNCaP cells, a prostate cancer cell line overexpressing 
prostate specific membrane antigen (PSMA, exhibits a hydrolase enzymic activity with a 
folate substrate). Following endolysosomal escape the AuNPs-PEI-FA.siRNA formulation 
produced enhanced endogenous gene silencing compared to the non-targeted formulation. 
Our results suggest both formulations have potential as non-viral gene delivery vectors in the 
treatment of prostate cancer.  
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1. Introduction 
Prostate cancer is among the leading causes of morbidity and mortality in men worldwide, 
with approximately 220,800 new cases diagnosed and 27,540 deaths in the United States in 
2015 [1]. Although current therapies using chemotherapeutics and small-molecule inhibitors 
have made significant progress, these strategies are limited by two primary issues: toxicity 
and lack of efficacy [2, 3]. Targeted delivery of therapeutics may help reduce toxicity and 
increase efficacy. Recently, novel nanomaterials tagged with relevant targeting ligands have 
been developed to interact with receptors highly expressed in tumour tissues for safe and 
efficient delivery of therapeutic cargos in the treatment of prostate cancer [4] [5] [6] [7].  
Advances in the genetic basis of diseases including cancer have helped identify gene targets 
associated with disease progression. The discovery that small interfering RNA (siRNA), one 
of RNA interference (RNAi) effectors could selectively downregulate any gene opened up 
the possibility of developing RNAi therapeutics [8]. However in order to translate RNAi into 
clinical use effective non-toxic delivery systems are essential. The development of novel 
biomaterials has facilitated the formulation of multifunctional nanoparticles (NPs) to deliver 
siRNA and these have been investigated in the treatment of both solid tumours and leukaemia 
[9] [10] [11]. 
Gold is a versatile material which can be processed into different shapes (i.e. sphere, rod etc.) 
and sizes, including particles in the nanometer size range (1~100 nm) [12]. Due to unique 
physicochemical properties gold nanoparticles (AuNPs) have been widely used as contrast 
agents, photothermal agents and radiosensitisers for cancer diagnosis and therapy [13]. In 
addition AuNPs exhibit the ability to bind amine and thiol groups allowing surface 
modification with functional moieties (i.e. stabilising groups, bioactive polymers and 
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targeting ligands) [14], this strategy has been utilised to facilitate targeted drug delivery for 
cancer therapy [15].  
In this study, two different bioconjugated AuNPs were synthesised as follows, 1) an anionic 
transferrin (Tf) tagged AuNP, AuNPs-PEG-Tf, and 2) a cationic folic acid (FA) tagged 
AuNP, AuNPs-PEI-FA, both designed to target cell surface receptors [transferrin receptor 
(TfR) and folate receptor (FR), respectively] overexpressed in prostate cancer cells. These 
AuNPs were fully characterised and their ability to achieve cell specific uptake was 
monitored in ordered to assess their potential as nontoxic gene delivery vectors. 
 
2. Experimental 
2.1 Materials and Chemicals  
Purified H2O (resistivity ≈ 18.2 MΩ cm) was used as a solvent for the synthesis of the 
AuNPs. All glassware was cleaned with aqua regia (3 parts of concentrated HCl and 1 part of 
concentrated HNO3), rinsed with distilled water, ethanol and acetone, and oven-dried before 
use. Tetrachloroauric acid trihydrate (HAuCl4.3H2O), L-ascorbic acid (C6H8O6), sodium 
citrate (C6H5Na3O7.2H2O), sodium hydroxide (NaOH), 4,7,10,13,16,19,22,25,32,-
35,38,41,44,47,50,53-Hexadecaoxa-28,29-dithiahexapenta-contanedioic acid di-N-
succinimidyl ester (NHS-PEG280-S-S-PEG280-NHS), transferrin, fluorescein isothiocyanate 
isomer I, folic acid, dry dimethyl sulfoxide (DMSO), triethylamine, branched PEI  (molecular 
weight, Mw ~ 2000), dicyclohexylcarbodiimide and  N-hydroxysuccinimide, were purchased 
from Sigma-Aldrich.                                                     
2.2 Synthesis of transferrin-conjugated gold nanoparticles 
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An aqueous solution of HAuCl4.3H2O (100 mL, 0.25 mmol L-1) was heated to 80 °C while 
stirring, 0.08 mL of 1 M NaOH were added, followed by rapid injection of 0.34 mL sodium 
citrate (340 mmol L-1) (Fig. 1). The colour of the solution changed from pale yellow to 
colourless instantly after addition of the sodium citrate; at ~ 5 min the colour changed to gray 
and then red at ~ 12 min; heating was stopped once the solution became deep red, and no 
furhter colour change was observed upto ~ 4.5 h after addition of sodium citrate. The solution 
was cooled to room temperature (RT) while stirring [16].  
A freshly prepared solution (1 mL, 0.5 mmol L-1) of NHS-PEG280-S-S-PEG280-NHS was 
added to 25 mL of AuNPs-citrate solution under stirring for 10 min to produce AuNPs-
PEG280-S-S-PEG280-NHS (thereafter referred as AuNPs-PEG-NHS) (Fig. 1).  
The pH of the AuNPs-PEG-NHS solution was adjusted to ~ 7.5-8. 0.4 mL transferrin (8.8 
μmol L-1) in citric buffer was added to 12.5 mL of AuNPs-PEG-NHS and incubated at RT 
under stirring for 4 h. The resultant AuNPs-PEG280-S-S-PEG280-transferrin (thereafter 
referred as AuNPs-PEG-Tf) (Fig. 1) were purified by centrifugation at 14,000 rpm for 20 min 
and resuspended in deionised water (DIW). 
In addition, a freshly made solution (400 µL, 1.5 mg for fluorescein isothiocyanate in 15 mL 
PBS buffer at pH 9) was added to 4 mL of the AuNPs-PEG-Tf solution and incubated with 
stirring at 4 °C in the dark overnight to produce fluorescein-labelled AuNPs-PEG-Tf. 
Fluorescein-labelled AuNPs-PEG-Tf were purified using centrifugation at 12,000 rpm for 5 
min at RT. 
2.3 Synthesis of folic acid-conjugated gold nanoparticles 
1.42 mL of PEI (2.3 mmol L-1) was added to 32.6 mL of HAuCl4.3H2O (1 mmol L-1) with 
stirring at RT; the colour of the solution changed from pale yellow to deep orange. When 0.5 
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mL of L-ascorbic acid (100 mmol L-1) was added the colour of the solution changed to red 
brownish at ~ 5 s. The solution was incubated at RT with stirring gently overnight to produce 
AuNPs-PEI (Fig. 1).  
Folic acid (0.25 g) was dissolved in 10 mL of dry DMSO (5.663 × 10-4 mol), followed by the 
addition of 0.125 mL of triethylamine (8.960 × 10-4 mol, 1.5 equivalents). The solution was 
sonicated for 10 min and stirred under Argon until the folic acid was dissolved. Subsequently, 
0.13 g of N-hydroxysuccinimide (11.295 × 10-4 mol, ~ 2 equivalents) and 0.235 g of 
dicyclohexylcarbodiimide (11.38 × 10-4 mol, ~ 2 equivalents) were added to the solution and 
the reaction mixture was left under stirring overnight at RT to produce the folic acid-NHS 
(Fig. 1). The byproduct, dicyclohexylurea, was removed by filtration. The solution of folic 
acid-NHS in DMSO (25 mg mL-1) was used without further purification. 
30 µL of folic acid-NHS (25 mg mL-1) was added to 3 mL of AuNPs-PEI and incubated with 
stirring at RT for 10 min. Subsequently 50 µL of 0.1 M NaOH was added to the solution and 
left under stirring at RT for 48 h in dark to produce the AuNPs-PEI-folic acid (thereafter 
referred as AuNPs-PEI-FA) (Fig. 1). The resultant AuNPs-PEI-FA solution was purified by 
centrifugation at 12,000 rpm for 5 min and the free folic acid-NHS in the supernatant was 
quantified using a CARY UV-Vis spectrophotometer with a Xenon lamp (240-900 nm range, 
0.5 nm resolution). 
2.4 Dynamic light scattering (DLS) 
Measurements of particle size and zeta potential were carried out using a Malvern Nano-ZS 
(Malvern Instruments, UK) at 25 ºC using the default non-invasive back scattering (NIBS) 
technique with a detection angle of 173º. Measurement for each sample was performed in 
DIW. 
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2.5 Transmission electron microscopy (TEM)  
A drop of AuNP solution was placed on a carbon-coated TEM copper grid (Quantifoil, 
Germany) and air-dried prior to analysis using a JEOL JEM-2100 TEM operated at 200 kV. 
All images were recorded on a Gatan 1.35 K × 1.04 K × 12 bit ES500W CCD camera. TEM 
images were analysed using Image J software. 
2.6 Scanning electron microscopy (SEM) 
AuNPs were deposited from solution onto a Si wafer and air-dried prior to analysis using a 
FEI 630 NanoSEM equipped with an Oxford INCA energy dispersive X-ray (EDX) detector 
operated at 5 kV. 
2.7 Cell culture and cytotoxicity 
PC-3 cells [a human prostate cancer cell line, European Collection of Cell Cultures 
(ECACC), UK] were maintained in RPMI-1640 medium (Sigma) supplemented with 10% 
fetal bovine serum (FBS). LNCaP cells [a human prostate cancer cell line, American Tissue 
Culture Collection (ATCC), USA] were maintained in RPMI-1640 medium supplemented 
with 10% FBS, 50 units mL-1 penicillin, 50 μg mL-1 streptomycin, 2 mM L-Glutamine, 
10 mM HEPES, 7.2 mM d-glucose and 1 mM Sodium Pyruvate. LNCaP cells were cultured 
and seeded in Poly-d-Lysine (1×) coated tissue culture flasks and wells [17]. All cells were 
grown in the incubator (ThermoForma) at 37 °C with 5 % CO2 and 95 % relative humidity. 
The cytotoxicity of AuNPs was estimated using the MTT assay with 3-(4, 5-Dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (Sigma) [18]. PC-3 (5,000 per well) and LNCaP 
(10,000 per well) cells were seeded within 200 µL growth media in 96-well plates one day 
before transfection. AuNPs were incubated with cells for 48 h under normal growth 
conditions. Following incubation the solutions were replaced with 200 µL fresh growth 
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medium, and 20 µL MTT stock (5 mg mL-1 in PBS) was added and incubated with cells for 4 
h at 37 ºC. The contents were then removed and 100 µL DMSO was added to dissolve the 
purple formazan products. The data were obtained at 590 nm using a microplate reader. The 
concentration of AuNPs leading to 50 % cell growth inhibition (IC50) was estimated from the 
plot of the percentage of viable cells versus the concentration of AuNPs for each treatment. 
2.8 Preparation and characterisation of AuNP.siRNA complexes 
Solutions of AuNPs-PEI and AuNPs-PEI-FA (500 µg mL-1) were added to the siRNA 
solutions (Negative Control siRNA, sense sequence 5’-UUC UCC GAA CGU GUC ACG U-
3’, prepared in RNase-free water following Sigma-Aldrich recommendations), at different 
mass ratios (MRs) of AuNPs to siRNA, followed by 1 h incubation with slightly shaking at 
RT. The ability of AuNPs to complex siRNA was analysed by gel retardation. Briefly, 
complexes of AuNPs and siRNA (containing 0.25 µg siRNA) at different MRs were loaded 
onto 1 % (w/v) agarose gels in Tris/Borate/EDTA (TBE) buffer containing SafeView (NBS 
Biologicals, UK). Electrophoresis was performed at 120 V for 30 min and the resulting gels 
were photographed under UV. 
Particle sizes and zeta potentials of AuNP.siRNA complexes were measured as described in 
Section 2.4. DIW (0.2 μm membrane-filtered) was added to the complexes and made up to 1 
mL, before measurement. The concentration of siRNA was fixed at 1 μg mL-1. 
2.9 Confocal Microscopy 
PC-3 cells (100,000 per well) were seeded in 6-well culture plates with glass bottoms 
(MatTek™). Cells were treated with 5 µg mL−1 AuNPs-citrate, AuNPs-PEG-NHS, AuNPs-
PEG-Tf and fluorescein-labelled AuNPs-PEG-Tf and incubated under the normal growth 
conditions for 24 h. Images were acquired on an Olympus FV 1000 microscope equipped 
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with differential interference contrast (DIC) and analysed using Olympus FV10-ASW 
software.  
LNCaP cells (300,000 per well) were seeded in 6-well culture plates with glass bottoms. 
Cells were treated with AuNPs-PEI-FA formulations (MR20) containing 50 nM FAM siRNA 
(sense sequence 5’-UUC UCC GAA CGU GUC ACG U-3’, modified by 6-FAM on 5’ of 
sense sequence, prepared in RNase-free water following Sigma-Aldrich recommendations) 
and incubated under the normal growth conditions for 24 h. In order to label late endosomes 
and lysosomes, 75 nM LysoTracker® Deep Red (Molecular Probes, Invitrogen) were added 
to cells for 30 min at 37 °C. The medium was then replaced with fresh growth medium. 
Images were acquired on an Olympus FV 1000 microscope and analysed using Olympus 
FV10-ASW software. 
2.10 Fluorescence activated cell sorting  
LNCaP (100,000 per well) and PC-3 (100,000 per well) cells were seeded in 24-well plates 
and incubated for 24 h under normal growth conditions. Cells were transfected by 25 and 50 
nM FAM siRNA complexed with AuNPs-PEI (MR20) and AuNPs-PEI-FA (MR20) and 
incubated for 24 h in normal growth medium. Following incubation cells were washed twice 
with PBS and trypsinised. Cells were subsequently centrifuged (1,000 rpm for 5 min) and re-
suspended in 1000 μL ice-cold PBS in Polystyrene Round-Bottom Tubes (Becton Dickinson). 
Ten thousands cells per sample were measured following the procedure outlined in Becton 
Dickinson FACScalibur manual. Fluorescein-positive cells (%) were displayed by Dot Plot. 
2.11 In vitro gene silencing 
LNCaP cells (200,000 per well) were seeded in 12-well plates and incubated for 24 h under 
normal growth conditions. Cells were then transfected by the AuNPs-PEI-FA formulation 
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(MR20) containing 50 nM RelA siRNA (sense sequence 5’-CCA UCA ACU AUG AUG 
AGU U-3’, prepared in RNase-free water; Integrated DNA Technologies, USA) for 24 h. 50 
nM naked RelA siRNA and the AuNPs-PEI-FA formulation containing 50 nM Negative 
Control siRNA were used as the negative controls. 
Following incubation total RNA was isolated from the cells using the 
GenElute™ Mammalian Total RNA Miniprep Kit (Sigma-Aldrich), according to the 
instructions supplied. First-strand cDNA was generated from total RNA samples using High-
Capacity cDNA Reverse Transcription Kits (Applied Biosystems). Gene expression was 
assessed by real-time quantitative PCR (qPCR) using the Applied Biosystems Real Time 
PCR System (model 7300). Assays were performed using appropriate primers for RelA and 
GAPDH (TaqMan, Applied Biosystems). Amplification was carried out by 40 cycles of 
denaturation at 95 °C (15 s) and annealing at 60 °C (1 min). The quantitative level of each 
RelA mRNA was measured as a fluorescent signal corrected according to the signal for 
GAPDH mRNA [19].  
2.12 Statistics 
The difference between two mean values was analysed using Student’s t test. One-way 
analysis of variance (ANOVA) was used to compare multiple groups followed by 
Bonferroni's post hoc test. Statistical significance was set at *p < 0.05. 
 
3. Results and discussion 
3.1 Synthesis of bioconjugated gold nanoparticles  
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The starting materials AuNPs-citrate and AuNPs-PEI were synthesised in water using sodium 
citrate and ascorbic acid as reducing agents respectively [20, 21] (Fig. 1). The resulting 
AuNPs were characterised by UV-visible absorption spectroscopy, electron microscopy 
(TEM or SEM) and DLS (Fig. 2). For UV-visible measurements the AuNPs-PEI solution was 
diluted four times prior to measurement and readjusted to the same absorption as AuNPs-
citrate. In Fig. 2A the red shift of the plasmon absorption maximum (λmax) from 526 nm to 
560 nm was clearly observed; this shift was also accompanied with a further broadening of 
the absorbance band, which is usually attributed to higher oscillation modes (quadrupole, 
octupole absorption and scattering) that might also affect the extinction cross section with 
increasing size [22]. Therefore, the use of sodium citrate as both a reducing and stabilising 
agent at high temperature (80°C) allowed the production of AuNPs-citrate with diameter of ~ 
33 nm (measured using TEM, Figs. 2B and 2D). In contrast, the use of ascorbic acid as a 
reducing agent for the reduction of HAuCl4 in the presence of PEI as the stabilising agent led 
to the production of AuNPs with diameter of ~ 105 nm (measured using SEM, Figs. 2C and 
2E). In addition, results in Fig. 2F show that AuNPs-citrate had a negative surface charge of 
~ -45 mV and AuNP-PEI had a positive zeta potential of ~ +53 mV, indicating the high 
electrostatic stability afforded to the AuNPs by the citrate ions and PEI. The AuNPs-citrate 
and AuNPs-PEI are stable for more than one year when stored in the dark at 4°C.  
For the synthesis of the AuNPs-PEG-Tf (Fig. 1) AuNPs-citrate were first conjugated with an 
ethylene glycol linker oligomer NHS-PEG280-S-S-PEG280-NHS with fourteen ethylene glycol 
units, a disulfide (-S-S-) and an N-hydroxysuccinimide (NHS) reactive ester. The PEG 
oligomer has a dual role as a stabilising agent and as a chemical linker to enable reaction with 
the amino groups of the protein in water [23-27], therefore leading to a stable and active 
colloidal solution. AuNPs-PEG-NHS showed a significant increase (~ 4 nm, p < 0.01) in 
particle size (Fig. 3A) and a slight increase (~ 3 mV, p > 0.05) in zeta potential (Fig. 3B) 
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when compared to AuNPs-citrate, indicating successful PEGylation. The addition of NHS-
PEG280-S-S-PEG280-NHS resulted in the formation of an NHS functional PEG layer grafted 
on the AuNP surface, where NHS-PEG280-S is attached through a gold thiol (Au-S) bond and 
the NHS is available to the surface to react with the primary amine groups of the protein (Fig. 
1). The Tf was attached on the PEG layer through formation of an amide linkage (NHCO) 
between the amino groups of the protein and the NHS of the AuNPs-PEG-NHS (Fig.1). 
Although DLS results showed no significant difference in particle sizes between AuNPs-
PEG-NHS and AuNPs-PEG-Tf (Fig. 3A), the slower migration in gel electrophoresis 
indicated the successful attachment of Tf to AuNPs-PEG-NHS (Fig. S1).  
The synthesis of AuNPs-PEI-FA (Fig. 1) was adapted from a method previously described 
[28], where fluorescein was attached onto gadolinium oxide NPs capped with PEI. In this 
work the amines of PEI are reacted with the NHS of activated folic acid. The resulting 
AuNPs-PEI-FA showed a significant increase in particle size (~ 5 nm, p < 0.01) following 
attachment of folic acid-NHS onto AuNPs-PEI surface (Fig. 3C), while the zeta potential was 
found to decrease by ~ 7 mV (p < 0.01) (Fig. 3D). The attachment of folic acid onto AuNPs-
PEI was further confirmed using UV-visible spectroscopy, which allowed the quantification 
of the folic acid-NHS left in solution after centrifugation of the AuNPs-PEI-FA; the results 
indicate that ~ 50 % of the initial FA was grafted onto the AuNPs-PEI surface (Fig. S2).  
3.2 Cytotoxicity 
The cytotoxicity of the bioconjugated AuNPs was assessed in two human prostate cancer cell 
lines (LNCaP and PC-3) using an MTT assay (Fig. 4). In the LNCaP cell line, AuNPs-PEG-
Tf, AuNPs-PEI and AuNPs-PEI-FA displayed IC50 values of 103, 118 and 110 μg 
mL−1 respectively. Similar data were also observed in PC-3 cells, with IC50 values of 107, 
135 and 120 μg mL−1 for AuNPs-PEG-Tf, AuNPs-PEI and AuNPs-PEI-FA respectively. It 
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has been reported that toxicity of AuNPs is dependent on particle size, surface charge, 
morphology, surface chemistry, ligand types and the mechanisms of cellular uptake [29]. 
Previously, positively charged, surfactant-free AuNPs were synthesised in our laboratory by 
the reduction of AuCl3 using hydroxylamine hydrochloride (NH2OH·HCl) in the presence of 
L-cysteine methyl ester hydrochloride [HSCH2CH(NH2)COOCH3·HCl] as a capping agent 
[30]. These  L-cystein capped AuNPs demonstrated IC50 values ≈ 7 to 9 µg mL-1. When L-
cystein capped AuNPs were modified using PEG with different Mw, IC50 values were 
slightly increased up to 15 µg mL-1 [31]. Here we have demonstrated that the conjugation of 
Tf, FA or PEI (Mw 2,000) onto the AuNPs may significantly improve biocompatibility 
relative to our previously synthesised L-cysteine capped AuNPs. Based on cytotoxicity data in 
Fig. 4, the concentrations of bioconjugated AuNPs used for subsequent in vitro studies 
ensured cell viability of > 80%. 
3.3 Cellular uptake of transferrin-conjugated gold nanoparticles 
Transferrin receptors (TfR), a transmembrane glycoprotein responsible for cellular iron 
transport, are found at low levels on the surface of many normal cell types; however, elevated 
expression has been reported in a wide range of cancer cells, and is often associated with 
poor prognosis [32]. Recently, Tf-targeted drug delivery systems have been investigated in 
cancer therapy [33] [34] [35]. In this study the cellular uptake of AuNPs-PEG-Tf using PC-3 
cells (a human prostate cancer cell line known as overexpressing TfR [36]) was investigated.  
AuNPs are a very useful contrast agent as they can be visualised using a large variety of 
techniques, including differential interference contrast (DIC) microscopy [37]. In this study, 
DIC images indicated that grafting of Tf facilitated the uptake of AuNPs into PC-3 cells 
relative to controls including untreated cells and cells treated with untargeted AuNPs-citrate 
and AuNPs-PEG-NHS (Fig. 5).  
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In addition, fluorescein-labelled AuNPs-PEG-Tf were synthesised via the interaction between 
the amino groups of Tf and the reactive -N=C=S groups of the fluorescein isothiocyanate 
isomer I, known to form a stable thiourea bond [38]. It is important to note that the 
fluorescein isothiocyanate was used at ~ 7.5 equivalents, in order to ensure that fluorescein-
labelled AuNPs-PEG-Tf have free transferrin to target TfR. When PC-3 cells were incubated 
with fluorescein-labelled AuNPs-PEG-Tf for 24 h, confocal microscopy images indicated a 
definite fraction of AuNPs-PEG-Tf (green) inside PC-3 cells (Fig. S3) further confirming the 
cellular uptake of AuNPs-PEG-Tf. Unlike cationic NPs, which bind to negatively charged 
cell surfaces, the negatively charged AuNPs-PEG-Tf (~ -43 mV) are unlikely to undergo non-
specific cell uptake. In contrast, the uptake of these Tf-targeted NPs is most probably via 
receptor-specific uptake [39].  
The anionic nature of the AuNPs-citrate (~ -45 mV), used to synthesise the Tf-targeted NPs 
was not influenced by the conjugation of PEG-NHS (AuNPs-PEG-NHS ~ -42 mV) or further 
conjugation with Tf (AuNPs-PEG-Tf ~ -43 mV). Due to the anionic nature of the AuNPs-
PEG-Tf, negatively charged siRNA will not readily bind to the NPs. However, complexation 
of siRNA with protamine (a positively charged peptide) has been shown to produce 
complexes with an overall positive charge that can then interact electrostatically with 
negatively charged AuNPs [21]. The complexation of ‘protamine.siRNA’ using AuNPs-PEG-
Tf and the subsequent biological activity of these formulations will be investigated in future 
studies. 
3.4 Complexation of siRNA with folic acid-conjugated gold nanoparticles 
Folate receptors (FR) are known as a cellular membrane glycoprotein, consisting of three 
isoforms; being FRα, FRβ and FRγ [40]. FR binds folic acid and structurally related folic acid 
derivatives and mediates cellular delivery of these compounds. It is now known that FR is 
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overexpressed on the vast majority of cancer tissues including prostate cancer, while its 
expression is limited in healthy tissues [40]. Targeted delivery via FR can be employed to 
increase the efficacy and reduce the toxicity of therapeutic agents for cancer therapy [35] 
[41]. In this study FA was chosen as a second targeting ligand, and the ability to attach FA to 
the AuNPs as a delivery vector for siRNA was investigated.  
The formation of AuNPs (AuNPs-PEI and AuNPs-PEI-FA) and siRNA complexes via 
electrostatic interaction (positively charged amine groups on PEI and negatively charged 
siRNA) was examined by gel retardation (Fig. 6). The results indicate that complete 
complexation of siRNA with AuNPs-PEI took place from MR of 5 onwards (Fig. 6A); in 
contrast, the targeted NPs, AuNPs-PEI-FA did not achieve complete complexation of siRNA 
until MR of 20 onwards (Fig. 6B), suggesting that conjugation of folic acid onto AuNPs-PEI 
causes some degree of steric interference significantly reducing the siRNA binding capacity.   
Using DLS at MR20, the diameter of AuNPs-PEI-FA.siRNA complexes in DIW was 375 
± 25 nm (PDI = 0.4), which was significantly larger than that of the AuNPs-PEI-FA alone 
(118 ± 1 nm, PDI = 0.09) (p < 0.001). In addition, the surface charge of AuNPs-PEI-FA 
complexes (~ +20 mV) was significantly lower than that of AuNPs-PEI-FA alone (~ +46 
mV) (p < 0.001). These results further confirm the successful complexation of siRNA by the 
targeted AuNPs-PEI-FA.   
3.5 Receptor-mediated uptake of folic acid-conjugated nanoparticles 
LNCaP cells highly express the prostate-specific membrane antigen (PSMA) which exhibits 
folate hydrolase activity [42], while PC-3 cells do not express PSMA [43] or FR [44]. In this 
study, FAM siRNA was used to investigate the association and cellular uptake of AuNPs-
PEI.siRNA (MR20) and AuNPs-PEI-FA.siRNA complexes (MR20) in both LNCaP (receptor 
positive) and PC-3 (receptor negative) cells. As shown in Fig. 7, AuNPs-PEI failed to induce 
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cellular association of siRNA in LNCaP or PC-3 cells, this is most likely due to the fact that 
lower Mw PEI (i.e. 600, 1,200 and 1,800 kDa) is known to display poor transfection 
efficiency [45]. In contrast, the results of flow cytometry displayed a significantly (p < 0.001) 
greater cellular association of AuNPs-PEI-FA.siRNA formulation (up to 30%, at 50 nM 
siRNA) with LNCaP cells, while the number of fluorescein-positive PC-3 cells detected with 
the folic acid-targeted formulation was negligible (Fig. 7). These flow cytometry results 
imply that grafting of folic acid can enhance targeting of AuNPs to LNCaP cells through the 
FR-mediated pathway.  
3.6 Intracellular trafficking of folic acid-conjugated nanoparticles 
PEI promotes endosomal/lysosomal escape of nucleic acids via the proton sponge effect by 
which the H+ buffering capacity of polyamines triggers endosomal Cl− accumulation 
during acidification resulting in osmotic endosome swelling/disruption [46]. The intracellular 
trafficking of the AuNPs-PEI-FA.siRNA complex (MR20) was studied in LNCaP cells using 
FAM siRNA (Fig. 8). At 24 h incubation, FAM siRNA (green) was detected inside the cells 
and the absence of colocalisation with LysoTracker® Deep Red (red, a marker for late 
endosomes and lysosomes) (Fig. 8) suggests that the AuNPs-PEI-FA facilitated siRNA 
escape from the endolysosomes thus avoiding degradation of siRNA by endolysosomal 
enzymes [47] [48].  
3.7 Endogenous gene silencing of folic acid-conjugated nanoparticles  
Nuclear factor κ-B (NF-κB) is a widely studied transcription factor found in many cancers 
including prostate cancer, it is associated with expression of a number of genes associated 
with cell proliferation, angiogenesis, metastases, tumour promotion and evasion of apoptosis 
[49]. NF-κB has five gene products: RelA, RelB, c-Rel, NF-κB1 and NF-κB2. The ability of 
AuNPs-PEI-FA to deliver functional siRNA was studied using RelA siRNA to silence RelA 
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expression in LNCaP cells [50]. After 24 h incubation, RelA siRNA formulated with AuNPs-
PEI-FA (MR20) significantly downregulated RelA mRNA expression (p < 0.05) compared to 
naked RelA siRNA and the Negative Control siRNA (non-silencing) formulated with 
AuNPs-PEI-FA (MR20) (Fig. 9), suggesting that silencing of RelA is related to RNAi 
activity rather than cytotoxicity.  
It was noted however that the AuNP-PEI-FA.siRNA formulation (MR20) caused aggregation 
(> 1 µm) when incubated within 10% FBS containing growth medium for 24 h (data not 
shown). This implies that following systemic administration non-specific binding of serum 
proteins onto AuNP formulations may occur causing particle aggregation and subsequent 
clearance by the mononuclear phagocytic system [MPS, also known as the reticuloendothelial 
system (RES)]. This phenomenon known as opsonisation results in a short in vivo half-life 
[51]. One of the most widely studied approaches to avoid RES uptake is the addition of a 
PEG moiety to form so called ‘stealth’ particles [52]. The conjugation of PEG (i.e. SH-PEG) 
onto the AuNPs-PEI-FA is chemically feasible and will simultaneously improve the in vivo 
stability [53] [54] while maintaining the ability to complex siRNA and to target receptor-
positive prostate cancer cells.  
 
4. Conclusions 
This proof of concept study has shown that the synthesis of gold nanoparticles tagged with 
two different ligands namely transferrin and folic acid is feasible. In both cases receptor-
mediated cellular uptake occurred. The anionic AuNPs-PEG-Tf has potential to deliver 
cationic ‘protamine.siRNA’ to prostate cancer cells via TfR-specific uptake. The cationic 
AuNPs-PEI-FA were capable of complexing siRNA to form targeted NPs. This targeted 
formulation achieved FR-specific uptake of siRNA and facilitated successful gene 
18 
 
knockdown in prostate cancer cells without toxicity. These initial results highlight the 
potential to utilise AuNPs as targeted non-viral gene delivery vectors. Future modifications, 
including: 1) gold cores with different sizes; 2) PEG chains with various Mw and grafting 
density; and 3) varying the ratios of PEG and targeing ligands on the AuNPs, to optimise in 
vivo efficacy for prostate cancer therapy are possible. 
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Figure 1. A schematic representation of (A) transferrin-conjugated AuNPs (AuNPs-PEG-Tf) 
and (B) folic acid-conjugated AuNPs (AuNPs-PEI-FA). 
Figure 2. (A) UV-visible spectra of AuNPs-citrate and AuNPs-PEI; (B) TEM image of 
AuNPs-citrate (bar = 100 nm); (C) SEM image of AuNPs-PEI (bar = 5 µm); (D) Size of 
AuNPs-citrate (33 ± 5 nm) and (E) size of AuNPs-PEI (105 ± 15 nm) analysed using TEM 
and SEM, respectively; (F) Zeta potentials of AuNPs-citrate (-45 ± 2 mV, n = 3) and AuNPs-
PEI (53 ± 1 mV, n = 3) analysed using DLS. 
Figure 3. Measurements of particle size and zeta potential of AuNPs using DLS. (A) Particle 
sizes of AuNPs-citrate (33 ± 1 nm, PDI = 0.2, n = 3), AuNPs-PEG-NHS (37 ± 1 nm, PDI = 
0.2, n = 3) and AuNPs-PEG-Tf (38 ± 1 nm, PDI = 0.2, n = 3); (B) Zeta potentials of AuNPs-
citrate (-45 ± 2 mV, n = 3), AuNPs-PEG-NHS (-42 ± 1 mV, n = 3) and AuNPs-PEG-Tf (-43 
± 2 mV, n = 3); (C) Particle sizes of AuNPs-PEI (113 ± 1 nm, PDI = 0.07, n = 3) and AuNPs-
PEI-FA (118 ± 1 nm, PDI = 0.09, n = 3); (D) Zeta potentials of AuNPs-PEI (53 ± 1 mV, n = 
3) and AuNPs-PEI-FA (46 ± 1 mV, n = 3). (The particle distributions shown as inserts in A 
and C) 
Figure 4. Viability (MTT) of LNCaP and PC-3 cells treated with AuNPs (mean ± SD, n = 3). 
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Figure 5. Cellular uptake of Transferrin-conjugated AuNPs in PC-3 cells. PC-3 cells were 
treated with 5 µg mL−1 of AuNPs-citrate, AuNPs-PEG-NHS and AuNPs-PEG-Tf and 
incubated for 24 h. Images were acquired using transmitted light differential interference 
contrast (DIC) model of Olympus FV 1000 microscope (100 X). 
Figure 6. Complexation of siRNA (0.25 μg) with (A) AuNPs-PEI and (B) AuNPs-PEI-FA at 
different mass ratios (MRs) using gel retardation (1% agarose gel at 120 mV for 30 min). 
Figure 7. Fluorescein-positive PC-3 and LNCaP cells (%, mean ± SD) after 24 h exposure to 
AuNPs-PEI-FA.FAM siRNA (MR20, 25 and 50 nM siRNA) analysed using flow cytometry 
(PC-3 = receptor negative cells and LNCaP cells = receptor positive cells). (** p < 0.01 and 
*** p < 0.001 compared to the untreated control) 
Figure 8. A confocal microscope image showing the intracellular distribution of the AuNPs-
PEI-FA formulation (MR20) containing FAM siRNA (50 nM) in LNCaP cells at 24 h post-
exposure (40 X). Late endosomes and lysosomes were labelled with 75 nM LysoTracker® 
Deep Red (Green = FAM siRNA, Red = LysoTracker® Deep Red). 
Figure 9. Endogenous gene silencing in LNCaP cells by RelA siRNA (50 nM) formulated 
with AuNPs-PEI-FA (MR20) after 24 h exposure. Naked RelA siRNA (50 nM) and Negative 
Control (non-silencing) siRNA (50 nM) formulated with AuNPs-PEI-FA (MR20) were used 
as controls (NS = no significance, *p < 0.05 compared to formulation containing Negative 
Control siRNA). (Mean ± SD, n = 3) 
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